Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes.

Abstract

The cryopyrin-associated periodic syndromes (CAPS) are a group of rare inherited inflammatory diseases associated with overproduction of IL-1β. Canakinumab, developed by Novartis AG (Basel, Switzerland), is an intravenously or subcutaneously administered, fully human monoclonal antibody that neutralizes the bioactivity of human IL-1β. Canakinumab has promising clinical safety and pharmacokinetic properties, and has demonstrated potential for the treatment of CAPS. Canakinumab was recently granted EU orphan drug status for systemic-onset juvenile idiopathic arthritis, and early clinical trials have established that administration of canakinumab every 2 weeks is both safe and effective. Subcutaneous canakinumab (approved formulation) offers some advantages over the existing IL-1β-blocking treatment, anakinra, which must be injected daily and is often not well tolerated by patients. The long-term safety of all targeted anti-IL-1 therapies in CAPS remains an unanswered question owing to the relatively short clinical experience with these agents; as canakinumab produces sustained IL-1 suppression, vigilance is necessary to diagnose the development of adverse events, especially any associated infections.

• Authors: Leigh D Church, Michael F McDermott
• Journal: Expert review of clinical immunology (Expert Rev Clin Immunol) Vol. 6 Issue 6 Pg. 831-41 (Nov 2010) ISSN: 1744-8409 [Electronic] England
• PMID: 20979548 (Publication Type: Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Interleukin 1 Receptor Antagonist Protein
• Interleukin-1beta
• canakinumab

Topics

• Antibodies, Monoclonal (administration & dosage, adverse effects, pharmacokinetics, pharmacology)
• Antibodies, Monoclonal, Humanized
• Arthritis, Juvenile (diet therapy, immunology)
• Clinical Protocols
• Clinical Trials as Topic
• Cryopyrin-Associated Periodic Syndromes (drug therapy, immunology)
• Europe
• Humans
• Interleukin 1 Receptor Antagonist Protein (therapeutic use)
• Interleukin-1beta (antagonists & inhibitors, immunology)